Patents/Inventors

Jens-peter Volkmer

Menlo Park, CAUS11 patents

13 Patents

US123184482025
Use of TLR Agonist and Anti-cd47 Agent to Enhance Phagocytosis of Cancer Cells
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US122747462025
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Forty Seven, LLC
0 cites
US122583992025
Methods for Achieving Therapeutically Effective Doses of Anti-cd47 Agents
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US122584032025
Methods for Treating Myeloma by Achieving Therapeutically Effective Doses of Anti-cd47 Antibody
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US121940932025
Dosing Parameters for CD47 Targeting Therapies to Hematologic Malignancies
Forty Seven, LLC
0 cites
US120374022024
Treatment of Cancer with Dual Targeting of CD47 and EGFR
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US118914502024
Anti-cd47 Agent-based Treatment of Cd20-positive Cancer
Forty Seven, Inc.
0 cites
US118021532023
Anti-cd47 Agent-based Ovarian Cancer Therapy
Forty Seven, Inc.
0 cites
US117664542023
Use of TLR Agonist and Anti-cd47 Agent to Enhance Phagocytosis of Cancer Cells
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US117534802023
Anti-sirp-alpha Antibodies and Related Methods
Forty Seven, Inc.
0 cites
US117186702023
Methods for Determining and Achieving Therapeutically Effective Doses of Anti-cd47 Agents in Treatment of Cancer
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US117186752023
Disrupting FC Receptor Engagement on Macrophages Enhances Efficacy of Anti-sirpalpha Antibody Therapy
The Board Of Trustees Of The Leland Stanford Junior University
0 cites
US116034042023
Methods for Treating Cancer by Achieving Therapeutically Effective Doses of Anti-cd47 Antibody
The Board Of Trustees Of The Leland Stanford Junior University
0 cites